Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -30564.79% is 82% below its 5-year average of -16779.34%, around the middle of its 5-year range (-96440.00%–-1138.55%).
37.71% above its 12-month average of -49071.55%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -21221.21%.
EBITDA MARGIN
-30564.79%
EBITDA MARGIN AVG TTM
-49071.55%
EBITDA MARGIN AVG 3Y
-29288.87%
EBITDA MARGIN AVG 5Y
-16779.34%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+37.71%
CURRENT VS 3Y AVG
-4.36%
CURRENT VS 5Y AVG
-82.16%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
PAVmed Inc.
Market Cap
$17.07M
EBITDA Margin
-30564.79%
TTM Avg
-49071.55%
3Y Avg
-29288.87%
5Y Avg
-16779.34%
Market Cap
$16.84M
EBITDA Margin
-168.69%
TTM Avg
-262.41%
3Y Avg
-983.34%
5Y Avg
-3401.51%
Market Cap
$17.31M
EBITDA Margin
-521.61%
TTM Avg
-265.78%
3Y Avg
-984.51%
5Y Avg
-733.51%
Market Cap
$16.82M
EBITDA Margin
-1287.62%
TTM Avg
-2964.71%
3Y Avg
-1700.58%
5Y Avg
-1592.26%
Market Cap
$17.39M
EBITDA Margin
-23.24%
TTM Avg
-24.75%
3Y Avg
-25.93%
5Y Avg
-17.56%
Market Cap
$16.74M
EBITDA Margin
-65.27%
TTM Avg
-65.27%
3Y Avg
-407.18%
5Y Avg
-920.02%
Market Cap
$16.64M
EBITDA Margin
-82.81%
TTM Avg
-187.23%
3Y Avg
-342.47%
5Y Avg
-369.32%
Market Cap
$16.52M
EBITDA Margin
-579.88%
TTM Avg
-374.35%
3Y Avg
-344.55%
5Y Avg
-411.92%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PAVmed Inc. (PAVM) | $17.07M | -30564.79% | -49071.55% | -29288.87% | -16779.34% |
| Marker Therapeutics, Inc. (MRKR)vs › | $16.84M | -168.69% | -262.41% | -983.34% | -3401.51% |
| Lipocine Inc. (LPCN)vs › | $17.31M | -521.61% | -265.78% | -984.51% | -733.51% |
| TScan Therapeutics, Inc. (TCRX)vs › | $16.82M | -1287.62% | -2964.71% | -1700.58% | -1592.26% |
| Cosmos Health Inc. (COSM)vs › | $17.39M | -23.24% | -24.75% | -25.93% | -17.56% |
| Palatin Technologies, Inc. (PTN)vs › | $16.74M | -65.27% | -65.27% | -407.18% | -920.02% |
| Bionano Genomics, Inc. (BNGO)vs › | $16.64M | -82.81% | -187.23% | -342.47% | -369.32% |
| Dyadic International, Inc. (DYAI)vs › | $16.52M | -579.88% | -374.35% | -344.55% | -411.92% |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.30M | N/A | N/A | N/A | N/A |
| BioCardia, Inc. (BCDA)vs › | $15.78M | -13679.31% | -8051.39% | -4553.85% | -5076.49% |
Gross Margin
-354.9%
EBITDA Margin
-30564.8%
Operating Margin
-30712.7%
Net Margin
-10794.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -21221.21% |
| 2026-03-31 | -36431.82% |
| 2025-12-31 | -13048.08% |
| 2025-09-30 | -96440.00% |
| 2025-06-30 | -78216.67% |
| 2025-03-31 | -67537.50% |
| 2024-12-31 | -51180.00% |
| 2024-09-30 | -1138.55% |
| 2024-06-30 | -1366.60% |
| 2024-03-31 | -1331.68% |
| 2023-12-31 | -1492.66% |
| 2023-09-30 | -1870.42% |
| 2023-06-30 | -9480.12% |
| 2023-03-31 | -4411.21% |
| 2022-12-31 | -21316.96% |
| 2022-09-30 | -29825.00% |
| 2022-03-31 | -10274.60% |
| 2021-12-31 | -6504.33% |
| 2021-09-30 | -6818.00% |
